Rosanna Apa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7249599/publications.pdf

Version: 2024-02-01

218381 243296 2,341 81 26 44 h-index citations g-index papers 83 83 83 2221 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Relationships Between Thyroid Hormones, Insulin-Like Growth Factor-1 and Antioxidant Levels in Hypothalamic Amenorrhea and Impact on Bone Metabolism. Hormone and Metabolic Research, 2019, 51, 302-308.	0.7	2
2	The resting metabolic rate in women with polycystic ovary syndrome and its relation to the hormonal milieu, insulin metabolism, and body fat distribution: a cohort study. Journal of Endocrinological Investigation, 2019, 42, 1089-1097.	1.8	12
3	"Hormone of darkness―and human reproductive process: direct regulatory role of melatonin in human corpus luteum. Journal of Endocrinological Investigation, 2019, 42, 1191-1197.	1.8	20
4	Increased fibulin-1 plasma levels in polycystic ovary syndrome (PCOS) patients: possible contribution to the link between PCOS and cardiovascular risk. Journal of Endocrinological Investigation, 2019, 42, 91-96.	1.8	9
5	Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study. Reproductive Sciences, 2018, 25, 269-275.	1.1	56
6	Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Gynecological Endocrinology, 2017, 33, 698-701.	0.7	24
7	Plasmatic and Intracellular Markers of Oxidative Stress in Normal Weight and Obese Patients with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 506-513.	0.6	14
8	Anti-Mýllerian hormone concentrations and antral follicle counts for the prediction of pregnancy outcomes after intrauterine insemination. International Journal of Gynecology and Obstetrics, 2016, 133, 64-68.	1.0	14
9	Hysterosalpingo-contrast-sonography (HyCoSy) in the assessment of tubal patency in endometriosis patients. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 186, 22-25.	0.5	8
10	Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women >=35 years: a RCT. Human Reproduction, 2015, 30, 179-185.	0.4	20
11	Psoriasis and polycystic ovary syndrome: a new link in different phenotypes. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 191, 101-105.	0.5	6
12	Expression, localization and control of activin A release from human umbilical vein endothelial cells. Growth Factors, 2015, 33, 243-249.	0.5	3
13	Urocortin 1 expression and secretion by human umbilical vein endothelial cells: In vitro effects of interleukin 8, interferon \hat{l}^3 , lipopolysaccharide, endothelin 1, prostaglandin F-2 \hat{l} ±, estradiol, progesterone and dexamethasone. Peptides, 2015, 74, 64-69.	1.2	7
14	A Possible Role of Polycystic Ovary Syndrome for Pregnancy Complications in Women with Psoriasis. Drug Development Research, 2014, 75, S64-6.	1.4	7
15	Endocrine disruptors and human reproductive failure: the inÂvitro effect of phthalates on human luteal cells. Fertility and Sterility, 2014, 102, 831-837.	0.5	41
16	Assessment of insulin resistance in lean women with polycystic ovary syndrome. Fertility and Sterility, 2014, 102, 250-256.e3.	0.5	38
17	Endocrine Disruptors and Human Corpus Luteum: <i>In vitro </i> Effects of Phenols on Luteal Cells Function. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2013, 31, 170-180.	2.9	9
18	Effects of Drospirenone–Ethinylestradiol and/or Metformin on CD4+CD28null T Lymphocytes Frequency in Women With Hyperinsulinemia Having Polycystic Ovary Syndrome: A Randomized Clinical Trial. Reproductive Sciences, 2013, 20, 1508-1517.	1.1	21

#	Article	IF	Citations
19	Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. Fertility and Sterility, 2013, 99, 936-942.	0.5	23
20	CD4+CD28null T lymphocyte frequency, a new marker of cardiovascular risk: relationship with polycystic ovary syndrome phenotypes. Fertility and Sterility, 2012, 98, 1609-1615.	0.5	16
21	InÂvitro effect of unacylated ghrelin and obestatin on human luteal cell function. Fertility and Sterility, 2012, 97, 991-996.	0.5	14
22	Could antispasmodic drug reduce pain during hysterosalpingoâ€contrast sonography (HyCoSy) in infertile patients? A randomized doubleâ€blind clinical trial. Ultrasound in Obstetrics and Gynecology, 2012, 39, 260-265.	0.9	26
23	The 312 <scp>N</scp> variant of the luteinizing hormone/choriogonadotropin receptor gene (<scp><i>LHCGR</i></scp>) confers up to 2·7â€fold increased risk of polycystic ovary syndrome in a <scp>S</scp> ardinian population. Clinical Endocrinology, 2012, 77, 113-119.	1.2	48
24	A prospective randomized noninferiority study comparing recombinant FSH and highly purified menotropin in intrauterine insemination cycles in couples with unexplained infertility and/or mild-moderate male factor. Fertility and Sterility, 2011, 95, 689-694.	0.5	17
25	CD4+CD28null T lymphocytes are expanded in young women with polycystic ovary syndrome. Fertility and Sterility, 2011, 95, 2651-2654.	0.5	22
26	Longâ€term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clinical Endocrinology, 2011, 75, 520-527.	1.2	46
27	Nicotine and cotinine affect the release of vasoactive factors by trophoblast cells and human umbilical vein endothelial cells. Placenta, 2011, 32, 153-160.	0.7	37
28	Prokineticin 1 mRNA expression in the endometrium of healthy women and in the eutopic endometrium of women with endometriosis. Fertility and Sterility, 2010, 93, 2145-2149.	0.5	20
29	Estrogens and androgens affect human luteal cell function. Fertility and Sterility, 2010, 94, 2257-2263.	0.5	11
30	Prokineticin 1, homeobox A10, and progesterone receptor messenger ribonucleic acid expression in primary cultures of endometrial stromal cells isolated from endometrium of healthy women and from eutopic endometrium of women with endometriosis. Fertility and Sterility, 2010, 94, 2558-2563.	0.5	17
31	Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase. Fertility and Sterility, 2009, 91, 1857-1863.	0.5	11
32	Endometriosis and human infertility: a new investigation into the role of eutopic endometrium. Human Reproduction, 2008, 23, 530-537.	0.4	82
33	Ultrasound in polycystic ovary syndrome the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. Human Reproduction, 2007, 22, 2501-2508.	0.4	65
34	Ghrelin Affects the Release of Luteolytic and Luteotropic Factors in Human Luteal Cells. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3239-3245.	1.8	50
35	Ghrelin in vitro modulates vasoactive factors in human umbilical vein endothelial cells. Fertility and Sterility, 2007, 88, 1158-1166.	0.5	8
36	Paracrine regulation of endometriotic tissue. Gynecological Endocrinology, 2007, 23, 574-580.	0.7	28

#	Article	IF	CITATIONS
37	Pituitary?ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma. Clinical Endocrinology, 2006, 65, 396-401.	1.2	15
38	Regulation of Vascular Endothelial Growth Factor Synthesis and Release by Human Luteal Cellsin Vitro. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2303-2309.	1.8	38
39	Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?. Human Reproduction, 2006, 21, 3108-3115.	0.4	78
40	Effects of Nicotine on Human Luteal Cells In Vitro: A Possible Role on Reproductive Outcome for Smoking Women1. Biology of Reproduction, 2005, 72, 628-632.	1.2	40
41	Effects of Insulin-Like Growth Factor I and II on Prostaglandin Synthesis and Plasminogen Activator Activity in Human Umbilical Vein Endothelial Cells. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 372-378.	1.8	8
42	Drospirenone for the Treatment of Hirsute Women with Polycystic Ovary Syndrome: A Clinical, Endocrinological, Metabolic Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2817-2823.	1.8	143
43	Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Human Reproduction, 2004, 19, 534-539.	0.4	45
44	Endometrial Evaluation in Superovulation Programs: Relationship with Successful Outcome. Annals of the New York Academy of Sciences, 2004, 1034, 211-218.	1.8	15
45	Insulin and GH secretion in adolescent girls with irregular cycles: Polycystic vs multifollicular ovaries. Journal of Endocrinological Investigation, 2003, 26, 305-311.	1.8	9
46	The effects of nitric oxide on prostanoid production and release by human umbilical vein endothelial cells. Life Sciences, 2003, 73, 2533-2542.	2.0	7
47	Interleukin-1Î ² Stimulates Progesterone Production byin VitroHuman Luteal Cells: Evidence of a Mediatory Role of Prostaglandins. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2690-2694.	1.8	25
48	Pituitary Adenylate Cyclase-Activating Polypeptide Modulates Plasminogen Activator Expression in Rat Granulosa Cell 1. Biology of Reproduction, 2002, 66, 830-835.	1.2	22
49	A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome. Human Reproduction, 2002, 17, 647-653.	0.4	9
50	A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertility and Sterility, 2001, 76, 326-331.	0.5	144
51	Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: A pilot prospective study. Journal of Endocrinological Investigation, 2001, 24, 483-490.	1.8	16
52	Recombinant versus Urinary Follicle-Stimulating Hormone in the Low-Dose Regimen in Anovulatory Patients with Polycystic Ovary Syndrome: A Safer and More Effective Treatment. Hormone Research in Paediatrics, 2001, 55, 224-228.	0.8	28
53	Evidence for a Functional Link between the Heme Oxygenase-Carbon Monoxide Pathway and Corticotropin-Releasing Hormone Release from Primary Cultures of Human Trophoblast Cells ¹ . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 317-323.	1.8	13
54	Endothelins Enhance Prostaglandin (PGE2 and PGF2α) Biosynthesis and Release by Human Luteal Cells: Evidence of a New Paracrine/Autocrine Regulation of Luteal Function. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 811-817.	1.8	29

#	Article	IF	CITATIONS
55	Evidence for a Functional Link between the Heme Oxygenase-Carbon Monoxide Pathway and Corticotropin-Releasing Hormone Release from Primary Cultures of Human Trophoblast Cells. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 317-323.	1.8	8
56	Endothelins Enhance Prostaglandin (PGE2 and PGF2Â) Biosynthesis and Release by Human Luteal Cells: Evidence of a New Paracrine/Autocrine Regulation of Luteal Function. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 811-817.	1.8	20
57	Expression and Relationship between Endothelin-1 Messenger Ribonucleic Acid (mRNA) and Inducible/Endothelial Nitric Oxide Synthase mRNA Isoforms from Normal and Preeclamptic Placentas. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2318-2323.	1.8	66
58	Paracrine Regulation of Insulin-Like Growth Factor I (IGF-I) and IGF-II on Prostaglandins F _{2α} and E ₂ Synthesis by Human Corpus Luteum <i>in Vitro</i> : A Possible Balance of Luteotropic and Luteolytic Effects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2507-2512.	1.8	13
59	Human Umbilical Vein Endothelial Cells: A New Source and Potential Target for Corticotropin-Releasing Factor. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2802-2806.	1.8	89
60	Effect of Anticardiolipin Antibodies on Prolactin and Insulinâ€Like Growth Factor Binding Proteinâ€1 Production by Human Decidual Cells. American Journal of Reproductive Immunology, 1999, 41, 209-216.	1.2	10
61	Endothelinâ€1: Expression and Role in Human Corpus Luteum. American Journal of Reproductive Immunology, 1998, 40, 370-376.	1.2	19
62	Involvement of Ovarian Steroids in the Opioid-Mediated Reduction of Insulin Secretion in Hyperinsulinemic Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1742-1745.	1.8	16
63	The Impact of Insulin Secretion on the Ovarian Response to Exogenous Gonadotropins in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 644-648.	1.8	103
64	Effect of Pituitary Adenylate Cyclase-Activating Peptide on Meiotic Maturation in Follicle-Enclosed, Cumulus-Enclosed, and Denuded Rat Oocytes 1. Biology of Reproduction, 1997, 57, 1074-1079.	1.2	46
65	Control of human luteal steroidogenesis: role of growth hormone-releasing hormone, vasoactive intestinal peptide, and pituitary adenylate cyclase-activating peptide. Fertility and Sterility, 1997, 68, 1097-1102.	0.5	26
66	Growth hormone stimulates androsterone synthesis by rat theca-interstitial cells. Molecular and Cellular Endocrinology, 1996, 118, 95-101.	1.6	21
67	Insulin-like growth factor (IGF)-I and IGF-II stimulate progesterone production by human luteal cells: role of IGF-I as mediator of growth hormone action. Fertility and Sterility, 1996, 66, 235-239.	0.5	21
68	Growth hormone-releasing factor stimulates meiotic maturation in follicle- and cumulus-enclosed rat oocyte. Molecular and Cellular Endocrinology, 1995, 112, 195-201.	1.6	15
69	Effect of corticotropin-releasing factor on the pituitary-ovary axis in human luteal phase. Gynecological Endocrinology, 1995, 9, 271-276.	0.7	2
70	Growth hormone induction of rat granulosa cell tissue-plasminogen activator expression and progesterone synthesis. Molecular and Cellular Endocrinology, 1994, 99, 153-159.	1.6	33
71	Growth hormone induces in vitro maturation of follicle- and cumulus-enclosed rat oocytes. Molecular and Cellular Endocrinology, 1994, 106, 207-212.	1.6	72
72	In vitro production of plasminogen activator by human granulosa cells. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 174-179.	1.8	6

#	Article	IF	CITATIONS
73	Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome. Fertility and Sterility, 1993, 59, 734-737.	0.5	26
74	Role of angiotensin II in the processes leading to ovulation. Biochemical Pharmacology, 1991, 42, 715-719.	2.0	12
75	Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. Human Reproduction, 1990, 5, 143-149.	0.4	54
76	LH surge induction by GnRH agonist at the time of ovulation. Gynecological Endocrinology, 1989, 3, 213-220.	0.7	47
77	Effect of Luteal Metoclopramide-Induced Hyperprolactinemia on Pituitary and Luteal Responsiveness to Gonadotropin-Releasing Hormone. Hormone Research, 1989, 31, 169-174.	1.8	2
78	Importance of echographic and endocrine monitoring for the assessment of ovulation by follicle stimulating hormone in polycystic ovarian disease. International Journal of Gynecology and Obstetrics, 1989, 28, 163-169.	1.0	1
79	Induction of ovulation by intermittent intravenous purified follicle-stimulating hormone in polycystic ovarian disease. Fertility and Sterility, 1987, 48, 1058-1061.	0.5	10
80	Successful Induction of Ovulation and Conception with Combined Gonadotropin-Releasing Hormone Agonist Plus Highly Purified Follicle-Stimulating Hormone in Patients with Polycystic Ovarian Disease. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 1253-1258.	1.8	57
81	Involvement of Ovarian Steroids in the Opioid-Mediated Reduction of Insulin Secretion in Hyperinsulinemic Patients with Polycystic Ovary Syndrome. , 0, .		8